Philip E. Thorpe
#160,319
Most Influential Person Now
Philip E. Thorpe's AcademicInfluence.com Rankings
Philip E. Thorpephilosophy Degrees
Philosophy
#9221
World Rank
#12750
Historical Rank
Logic
#6208
World Rank
#7700
Historical Rank

Philip E. Thorpebiology Degrees
Biology
#12646
World Rank
#16137
Historical Rank
Biochemistry
#2174
World Rank
#2319
Historical Rank

Download Badge
Philosophy Biology
Philip E. Thorpe's Degrees
- PhD Biochemistry University of Texas Southwestern Medical Center
- Doctorate Medicine University of Texas Southwestern Medical Center
Why Is Philip E. Thorpe Influential?
(Suggest an Edit or Addition)Philip E. Thorpe's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) (2727)
- Vascular Targeting Agents as Cancer Therapeutics (2004) (563)
- Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature (1997) (500)
- Increased exposure of anionic phospholipids on the surface of tumor blood vessels. (2002) (448)
- Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. (1995) (350)
- Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. (2000) (340)
- Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo (2002) (337)
- The Preparation and Cytotoxic Properties of Antibody‐Toxin Conjugates (1982) (253)
- Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. (2002) (246)
- Immunotoxins: magic bullets or misguided missiles? (1993) (224)
- New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. (1987) (223)
- A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. (2004) (212)
- Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. (1993) (209)
- Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. (2004) (193)
- Targeting Inside-Out Phosphatidylserine as a Therapeutic Strategy For Viral Diseases (2008) (191)
- Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. (2011) (183)
- Vascular endothelial growth factor as a marker of tumor endothelium. (1998) (178)
- Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies (2004) (167)
- Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. (1988) (162)
- The first international conference on vascular targeting: meeting overview. (2003) (159)
- Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. (2000) (145)
- Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. (1987) (143)
- Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice (2005) (142)
- Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. (2011) (141)
- Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. (1998) (141)
- In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors (2002) (140)
- An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. (1985) (139)
- Vascular targeting--a new approach to the therapy of solid tumors. (1994) (139)
- A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. (2005) (136)
- Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. (1985) (125)
- Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors (2000) (118)
- Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation (2013) (117)
- Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. (1981) (114)
- Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma (2009) (113)
- A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model (2004) (110)
- The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis (2001) (105)
- Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugate (1982) (101)
- Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. (2001) (98)
- Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. (1990) (98)
- Purification of ricin A1, A2, and B chains and characterization of their toxicity. (1986) (95)
- Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine (2008) (93)
- Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids (2007) (91)
- Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. (1984) (88)
- Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. (1988) (87)
- Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. (1991) (87)
- Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. (1990) (86)
- Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas (1988) (83)
- The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma (2001) (82)
- Expression of ricin A chain in Escherichia coli (1987) (82)
- Vascular endothelial growth factor and vascular targeting of solid tumors. (2001) (81)
- Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer (2004) (80)
- Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. (1987) (79)
- A novel "salting-out" procedure for the isolation of tumor-derived exosomes. (2014) (78)
- Antibody toxin conjugates: a perspective. (1988) (74)
- [16] Preparation of antibody—toxin conjugates (1985) (74)
- Immunotoxins containing ricin or its A chain. (1991) (74)
- The removal of carbohydrates from ricin with endoglycosidases H, F and D and α-mannosidase (1985) (72)
- Optimal conditions for the preservation of mouse lymph node cells in liquid nitrogen using cooling rate techniques. (1976) (72)
- Antibody-directed targeting of the vasculature of solid tumors (2004) (72)
- Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice (2006) (69)
- Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin (1978) (68)
- Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells* (2006) (66)
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors (2011) (65)
- Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. (2014) (63)
- Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. (1993) (61)
- A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. (1992) (61)
- Multimodality imaging of hypoxia in preclinical settings. (2010) (61)
- Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen (2004) (59)
- Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. (2008) (59)
- Microplate culture of mouse lymph node cells. I. Quantitation of responses to allogeneic lymphocytes endotoxin and phytomitogens. (1974) (56)
- Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines (2010) (55)
- Immunotoxins constructed with anti‐CD25 monoclonal antibodies and deglycosylated ricin a‐chain have potent anti‐tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice (1991) (54)
- The use of anti-ricin antibodies to protect mice intoxicated with ricin. (1985) (52)
- Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. (2000) (52)
- In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11 (1997) (50)
- The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. (1991) (49)
- VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. (2001) (49)
- Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. (2003) (49)
- An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A (1984) (48)
- Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. (1986) (48)
- Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants. (1987) (48)
- Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. (2011) (47)
- Cytotoxicity of a recombinant ricin‐A‐chain fusion protein containing a proteolytically‐cleavable spacer sequence (1990) (47)
- Organ‐specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene‐targeting of the PI3K regulatory isoforms p85α, p55α, and p50α (2009) (45)
- Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. (2003) (43)
- A new method for radiochemical separation of arsenic from irradiated germanium oxide. (2005) (43)
- An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. (1988) (41)
- Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. (1988) (40)
- Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin (1987) (40)
- Exogenous BH4/Bcl-2 Peptide Reverts Coronary Endothelial Cell Apoptosis Induced by Oxidative Stress (2004) (40)
- Neuronotoxic effects of monoclonal anti-Thy 1 antibody (OX7) coupled to the ribosome inactivating protein, saporin, as studied by suicide transport experiments in the rat (1989) (39)
- The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. (1989) (38)
- The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. (2005) (37)
- Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment. (1980) (36)
- Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. (1988) (36)
- Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. (1998) (36)
- The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. (2005) (36)
- Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein fromSaponaria officinalis (1987) (36)
- Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins (1994) (34)
- An Orthotopic Lung Tumor Model for Image-Guided Microirradiation in Rats (2010) (34)
- Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and non-parenchymal cells of rat liver. (1985) (33)
- Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. (2006) (33)
- Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. (2011) (31)
- Quantitative assessment of tumor oxygen dynamics: Molecular imaging for prognostic radiology (2002) (31)
- A new method for the labelling of proteins with radioactive arsenic isotopes (2006) (30)
- Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. (1981) (29)
- Cocktails of ricin a‐chain immunotoxins against different antigens on hodgkin and sternberg‐reed cells have superior anti‐tumor effects against H‐RS cells in vitro and solid Hodgkin tumors in mice (1995) (29)
- Tumor infarction by targeting tissue factor to tumor vasculature. (2000) (29)
- Preparation of antibody-toxin conjugates. (1985) (29)
- Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. (2011) (28)
- Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors (2010) (27)
- AN IMMUNOTOXIN OF RICIN A CHAIN CONJUGATED TO THYROGLOBULIN SELECTIVELY SUPPRESSES THE ANTI-THYROGLOBULIN AUTOANTIBODY RESPONSE (1983) (26)
- COADMINISTRATION OF LOW‐DOSE LIPOPOLYSACCHARIDE AND SOLUBLE TISSUE FACTOR INDUCES THROMBOSIS AFTER RADIOSURGERY IN AN ANIMAL ARTERIOVENOUS MALFORMATION MODEL (2007) (26)
- Targeting anionic phospholipids on tumor blood vessels and tumor cells. (2010) (26)
- Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti‐T cell immunotoxins (1987) (25)
- Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine (2013) (25)
- Semaphorin 3 B ( SEMA 3 B ) induces apoptosis in lung and breast cancer , whereas VEGF 165 antagonizes this effect (2004) (25)
- Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4 (2009) (25)
- Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. (2012) (24)
- Phosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function (2013) (22)
- The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution. (1987) (22)
- Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis (2016) (22)
- Characterization of the cell‐surface procoagulant activity of T‐lymphoblastoid cell lines (2004) (21)
- Targeting the vasculature of solid tumors (1993) (21)
- Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. (2014) (21)
- Phosphatidylserine externalization and membrane blebbing are involved in the nonclassical export of FGF1 (2012) (21)
- Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts (2016) (20)
- Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. (1991) (20)
- An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A. (1984) (20)
- Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. (2001) (18)
- Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. (1988) (18)
- Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. (2015) (18)
- Retargeting Adenoviral Vectors to Improve Gene Transfer into Tumors (2010) (17)
- Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-1 antibody-ricin conjugate. (1985) (16)
- Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver. (1988) (16)
- Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. (1988) (15)
- Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. (1988) (15)
- Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. (1994) (15)
- Antibody Toxin Conjugates: A Perspective (Part 1 of 2) (1988) (15)
- Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells. (1996) (14)
- Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco. (2016) (14)
- Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 (2011) (14)
- Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. (1985) (14)
- Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin (2005) (13)
- A comparison of the in vitro and in vivo activities of conjugates of anti-mouse lymphocyte globulin and abrin. (1982) (12)
- Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. (1994) (12)
- Erratum: In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors (Proceedings of the National Academy of Sciences of the United States of America (June 11, 2002) 99:12 (7866-7871)) (2002) (12)
- TAT-BH4 counteracts Abeta toxicity on capillary endothelium. (2007) (11)
- Circular dichroism of isolated ricin A- and B-chains. (1988) (11)
- Targeting toxins — the retiarian approach to chemotherapy (1981) (11)
- Anti‐tumor and anti‐angiogenic effects in mice of heparin conjugated to angiostatic steroids (1995) (11)
- Elimination of leukaemic cells from rodent bone marrow in vitro with antibody-ricin conjugates: Implications for autologous marrow transplantation in man (1982) (10)
- The removal of carbohydrates from ricin with endoglycosidases H, F and D and alpha-mannosidase. (1985) (9)
- UTSW Small Animal Positron Emission Imager (2006) (9)
- Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas (2004) (9)
- Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins. (1988) (8)
- Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. (2011) (7)
- Strategies for labeling proteins with PARACEST agents. (2011) (6)
- Enzymic removal of two oligosaccharide chains from ricin B‐chain (1986) (6)
- Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. (2003) (6)
- Coexpression of MUC 1 Glycoprotein with Multiple Angiogenic Factors in Non-Small Cell Lung Cancer Suggests Coactivation of Angiogenic and Migration Pathways 1 (2000) (5)
- Immunotoxins: magic bullets or misguided missiles? (1993) (5)
- Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins. (1988) (5)
- Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection (2017) (4)
- Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats. (1983) (4)
- A simple and rapid method for purifying the extracellular domain of human tissue factor. (1998) (4)
- Role of the B-Chain in the Cytotoxic Action of Antibody-Ricin and Antibody-Abrin Conjugates (1984) (4)
- Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. (2012) (4)
- A novel membrane-acting immunotoxin, the immunolysin, with therapeutic potential. (1992) (3)
- Abstracts of papers and posters (2005) (3)
- Cryopreservation of mouse lymphocytes (1974) (3)
- Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model (2007) (3)
- Abstract #5463: Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice (2009) (2)
- The Potential of Membrane-Acting Toxins for Targeted Cancer Therapy (1988) (2)
- Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin. (1984) (2)
- What's new: Immunotoxins (1986) (2)
- Abstract 4395: Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody (2012) (2)
- Selected Antibodies and Duramycin Peptides that bind to anionic phospholipids and aminophospholipids and their uses in the treatment of viral infections and cancer. (2003) (2)
- Identification of a tyrosine residue in the saccharide binding site of ricin B‐chain using N‐[14C]acetylimidazole (1987) (2)
- Abstract 621: Targeting phosphatidylserine to improve androgen deprivation therapy of prostate cancer (2011) (2)
- Phosphatidylserine-targeting antibody induces M1 macrophage polarization, promotes myeloid derived suppressor cell differentiation and boosts tumor-specific immunity (2013) (1)
- Anti‐viral Effects of Phosphatidylethanolamine‐targeting agents (2008) (1)
- [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]. (1992) (1)
- IBC’s 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society (2012) (1)
- Abstract 4632: Phosphatidylserine-targeting ‘betabodies’ for the treatment of cancer (2012) (1)
- Antibody-Toxin Conjugates as Anti-Cancer Agents (1984) (1)
- Vascular Endothelial Growth Factor Isoforms Display Distinct Activities in Promoting Tumor Angiogenesis at Different Anatomic Sites 1 (2001) (1)
- Targeting Inside‐Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer (2006) (1)
- Abstract 3643: Phosphatidylserine-targeting antibody combined with Sorafenib has strong anti-tumor activity against human hepatocellular carcinomas in mice (2011) (1)
- Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential Broad-Spectrum Antiviral Therapy (2010) (1)
- ANTIBODY-MEDIATED TARGETING OF “INSIDE-OUT” ANIONIC PHOSPHOLIPIDS IN VIRAL DISEASE (47.21) (2007) (1)
- / rGel 121 by the Vascular Targeting Agent VEGF Inhibition of Prostate Tumor Growth and Bone Remodeling (2006) (1)
- Antibody-Toxin Conjugates as Potential Therapeutic Agents (1982) (1)
- The Development of Ricin A-Chain Immunotoxins for Clinical Trials in Patients with Hodgkin’s Disease (1992) (1)
- [Immunotoxin: from the idea of "magic bullets" to clinical applications]. (1990) (1)
- New strategies for therapy of breast cancer (2004) (0)
- Antiphospholipid Antibodies Promote Leukocyte-Endothelial Cell Adhesion by Antagonizing Endothelial NO Synthase Via b2GPI and ApoER2. (2009) (0)
- Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium1 (2006) (0)
- Antibody Targeting of Tumor Vasculature (2002) (0)
- The development of immunotoxins for the treatment of B-cell lymphoma (1993) (0)
- Anti-phosphatidylserine Antibodies As A Potential New Therapy Against Choroidal Neovascularization (2012) (0)
- Chimeric proteins containing ricin A chain. (1992) (0)
- Use of anti-aminophospholipid antibodies for cancer treatment (1999) (0)
- Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium 1 (2006) (0)
- The Effect of Chemical Deglycosylation of Ricin A-Chain on the Therapeutic Potential of Ricin A-Chain Immunotoxins (1988) (0)
- Abstract 5330: Phosphatidylserine-targeting antibody enhances survival benefit of androgen deprivation therapy in mice bearing syngeneic prostate cancer (2010) (0)
- Method for treating cancer using antibodies aminofosfolipìdios (1999) (0)
- Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines (1992) (0)
- Targeting Toxins by Conjugation to Antibodies: The Effect of the Linkage Group on Biological Activity (1984) (0)
- Methods of cancer treatment using therapeutic conjugates that bind to aminophospholipids. (1999) (0)
- Selected antibodies that bind to aminophospholipids and its use in cancer treatment (2003) (0)
- Use of immunoconjugates for diagnosis and / or treatment of vascularized tumors (1993) (0)
- Abstract 3651: Phosphatidylserine-targeting antibody induces differentiation of myeloid-derived suppressor cells into M1-like macrophages (2011) (0)
- Selected antibodies that bind to aminophospholipids and their use in therapy such as cancer (2003) (0)
- Anti-tumor Effects of Monoclonal Antibody-ricin Conjugates In Vitro and In Vivo (1988) (0)
- Overcoming cisplatin-resistance of breast cancer in mice by co-administering cisplatin and anti-phosphatidylserine antibody, 3G4 (2006) (0)
- Antibody-ricin conjugates (1984) (0)
- Use of immunoconjugates for diagnosis and / or therapy of tumors vascularizaos. (1993) (0)
- Expression of Vascular Endothelial Growth Factor (VEGF) Associated with Its Receptor (VEGFR) in Relation to Tissue Factor (TF) in Human Breast Cancer Tissue. (2005) (0)
- Methods and compositions of tissue factor to coagulation and treatment of tumors (1998) (0)
- Compositions and methods for the treatment of cancer through inhibition selective of vegf. (2000) (0)
- Erratum: Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocyte globulin (Nature (1978) 271, (752)) (1978) (0)
- Vasculature Antibody-directed Targeting of Tissue Factor to Tumor Infarction of Solid Hodgkin ' s Tumors in Mice by Updated Version (2006) (0)
- Antibodies that bind to anionic phospholipids and aminophospholipids, and their use for the treatment of viral infections (2003) (0)
- Immunotoxins against the vasculature of human Hodgkin’s lymphoma in SCID mice (2007) (0)
- Reply to the letter of Griffioen et al. on endoglin/CD 105 as a tumor endothelial treatment target (1996) (0)
- Selective killing of malignant cells fey antibody-ricin conjugates (‘immunotoxins’) (1990) (0)
- Compositions and methods of cancer treatment by the selective inhibition of VEGF (2000) (0)
- Fusion proteins composed of mouse IgG2a Fc and mouse beta-2-glycoprotein 1 bind to endothelial cells with exposed phosphatidylserine (2007) (0)
- Abstract 5232: Phosphatidylethanolamine is a marker of tumor vasculature and can be used as a target for optical imaging (2010) (0)
- Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease (1990) (0)
- Abstract 1244: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice. (2013) (0)
- Monoclonal antibodies as pharmacological agents: Comparison of the antitumour effects of two anti-thy 1.1 abrin a conjugates prepared with different coupling agents (1985) (0)
- Anti-phosphatidylserine monoclonal antibody, 3G4, enhances the anti-tumor effects of docetaxel against human breast cancer (2004) (0)
- Selective direction of ricin to hepatic parenchymal cells (1982) (0)
- The effect of abrin, anti-lymphocyte globulin and their conjugates on the immune response of mice to sheep red blood cells (1981) (0)
- On the immune response of mice to sheep red blood cells. (1981) (0)
- Antibodies binding to anionic phospholipides and aminophospholipides and their use in the treatment of virus infections (2003) (0)
- An Anti-Phosphatidylserine (PS) Antibody, Tarvacin™ That Targets Tumor Blood Vessels Does Not Affect Platelet Function In Vitro. (2005) (0)
- Anatomic Sites Activities in Promoting Tumor Angiogenesis at Different Vascular Endothelial Growth Factor Isoforms Display Distinct Updated (2001) (0)
- Antibody Toxin Conjugates: A Perspective (Part 2 of 2) (1988) (0)
- Angiopoietin-2 transfection does not enhance the sensitivity of the NCI-H358 lung tumor to VEGF-neutralizing therapy (2002) (0)
- Contents of Volume 5 (2002) (2004) (0)
- Image quantification of sentinel node uptake using 99Tcm-Nanocoll in 14 patients (1999) (0)
- In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A. (1987) (0)
- Ligand-Directed Destruction of Tumor Vasculature (2002) (0)
- of Tumor Blood Vessels Increased Exposure of Anionic Phospholipids on the Surface Updated (2002) (0)
- Abstract 1919: Phosphatidylserine on dying tumor cells suppresses dendritic cell activation and inhibits tumor immunity: reversal with PS-targeting antibody (2010) (0)
- Immunotargeting of tumor vessels for cancer therapy (1997) (0)
- Inhibition of pancreatic tumor growth and metastasis in mice by targeting inside-out phospholipids on tumor vasculature (2005) (0)
- Methods and compositions for specific coagulation of tumor vasculature (1995) (0)
- Antibody toxin conjugates (1988) (0)
- The First International Conference on Vascular Targeting : Meeting Overview 1 (2003) (0)
- Combined targeting of exposed phosphatidylserine, CD47 and CD54 on human pancreatic tumor cells in a mouse xenograft model of human pancreatic cancer (P4455) (2013) (0)
- Following are the abstracts from the Fourth Annual Meeting of the Society for Molecular Imaging (2005) (0)
- In vivo imaging of tumor vascular endothelial cells (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Philip E. Thorpe?
Philip E. Thorpe is affiliated with the following schools: